Journament

Keyword Connections - tyrosine kinase inhibitors Keywords

Connection Type	Connection
Journals	Bioorganic chemistry Scientific reports PloS one British journal of clinical pharmacology Cureus journal of clinical oncology : official journal of the american society of clinical oncology Journal of hospital medicine Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners Annals of hematology
Research Groups	No Research Group Connected
Bibliographies	[1] Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis. [2] Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. [3] Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. [4] Nitrification inhibitors can increase post-harvest nitrous oxide emissions in an intensive vegetable production system. [5] checkpoint molecule pd-1-assisted cd8+ t lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors [6] tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report [7] long-term disease control in advanced renal cell cancer with brain metastases with pazopanib (case report and literature review) [8] efficacy of vandetanib in treating locally advanced or metastatic medullary thyroid carcinoma according to recist criteria: a systematic review and meta-analysis [9] mechanistic systems modeling to improve understanding and prediction of cardiotoxicity caused by targeted cancer therapeutics [10] Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. [11] A systematic review of medicinal plants used against Echinococcus granulosus. [12] the infection of cucumber (cucumis sativus l.) roots by meloidogyne incognita alters the expression of actin-depolymerizing factor (adf) genes, particularly in association with giant cell formation [13] a combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer [14] tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients [15] Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer. [16] Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis. [17] RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice [18] checkpoint molecule pd-1-assisted cd8+ t lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors [19] can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? [20] tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report [21] chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients [22] importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance [23] Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2 [24] severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review [25] Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. [26] increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis [27] alignment independent 3d-qsar, quantum calculations and molecular docking of mer specific tyrosine kinase inhibitors as anticancer drugs [28] tyrosine kinase inhibitors and pregnancy [29] outcomes of research biopsies in clinical trials of egfr mutation-positive non-small cell lung cancer patients pretreated with egfr-tyrosine kinase inhibitors [30] tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients [31] Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors. [32] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.